Comparative effectiveness and cardiovascular safety of romosozumab versus teriparatide in patients with osteoporosis: a population-based cohort study
Authors' conclusion
In patients with osteoporosis, there was no significant difference in the prevention of nonvertebral fracture and hip fracture between romosozumab and teriparatide. In addition, the risk of MACE was comparable between the two drugs.
Study context
- Population
- Patients aged 50 years or older initiating romosozumab or teriparatide for osteoporosis, Japanese administrative claims database (March 2019 to October 2022)
- Participants
- 49,104 patients
- Exposure
- Romosozumab vs teriparatide
- Romosozumabn = 16,125
- Teriparatiden = 32,979reference
- Outcome
- Nonvertebral fracture
- Follow-up
- 365 days
Methodological detailsactive comparator, new user cohort design, inverse probability of treatment weighting, Japanese administrative claims database
- Active comparator
- New user cohort design
- Inverse probability of treatment weighting
- Japanese administrative claims database
Main finding
As reported in the abstract
Each group vs teriparatideWeighted incidence rate difference, events per 100 person-years (95% CI)
Romosozumab
−0.08(−0.34 to 0.17)
Each group vs teriparatideWeighted hazard ratio (95% CI)
Romosozumab
0.95(0.81–1.12)
Observational data: associations, not effects.
Further findings
| Outcome | Weighted incidence rate difference (events per 100 person-years) (95% CI) | |
|---|---|---|
| Hip fracture · 365 daysRomosozumabvs TeriparatideEffectiveness outcome | 0.00 (−0.16 to 0.16) | |
| −0.2−0.100.10.2Difference, events per 100 person-years (linear scale) |
| Outcome | Weighted HR (95% CI) | |
|---|---|---|
| Hip fracture · 365 daysRomosozumabvs TeriparatideEffectiveness outcome | 0.99 (0.76–1.29) | |
| 0.512Weighted hazard ratio (log scale) |
Safety
| Outcome | Weighted incidence rate difference (events per 100 person-years) (95% CI) | |
|---|---|---|
| MACE · 365 daysRomosozumabvs Teriparatide | −0.06 (−0.20 to 0.09) | |
| −0.3−0.2−0.100.1Difference, events per 100 person-years (linear scale) |
| Outcome | Weighted HR (95% CI) | |
|---|---|---|
| MACE · 365 daysRomosozumabvs Teriparatide | 0.90 (0.68–1.19) | |
| 0.512Weighted hazard ratio (log scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Comparative effectiveness and cardiovascular safety of romosozumab versus teriparatide in patients with osteoporosis: a population-based cohort study. Osteoporos Int. Published 25 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →